SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2) * AP Pharma Inc. (Name of Issuer) Common stock, par value \$0.01 per share -----(Title of Class of Securities) 00202J203 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) (Page 1 of 11 Pages) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 00202J203 13G Page 2 of 11 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Capital, L.P. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) $|_{-}|$ (b) |X| SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5. SOLE VOTING POWER 0 NUMBER OF 6. SHARED VOTING POWER SHARES BENEFICIALLY 690,115

PE	ORTING RSON 0 ITH
	8. SHARED DISPOSITIVE POWER
	690,115
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	690,115
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* $\mid _ \mid$
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	2.23%
12.	TYPE OF REPORTING PERSON*
	PN

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |_|

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.23%

PN

4.25%

PN

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.25%

CO

6.48%

CUSIP No.	00202J203
Item 1(a).	Name of Issuer:
	AP Pharma Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	123 Saginay Drive Redwood City, CA 94063
Item 2(a).	Name of Person Filing:
	James E. Flynn, Deerfield Capital, L.P., Deerfield Special Situations Fund, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund International Limited
Item 2(b).	Address of Principal Business Office, or if None, Residence:
	James E. Flynn, Deerfield Capital, L.P., Deerfield Special Situations Fund, L.P., Deerfield Management Company, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017, Deerfield Special Situations Fund International Limited, c/o Bisys Management, Bison Court, Columbus Centre, P.O. Box 3460, Road Town, Tortola, British Virgin Islands
Item 2(c).	Citizenship:
	Deerfield Capital, L.P. and Deerfield Special Situations Fund, L.P Delaware limited partnerships, Deerfield Management Company, L.P New York limited partnership, Deerfield Special Situations Fund International Limited- British Virgin Islands corporation James E. Flynn - United States citizen
Item 2(d).	Title of Class of Securities:
	Common Stock
Item 2(e).	CUSIP Number:
	00202J203
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a)	[_] Broker or dealer registered under Section 15 of the Exchange Act.
(b)	[_] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	[_] Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	[_] Investment company registered under Section 8 of the Investment Company Act.
(e)	<pre>[_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);</pre>

<pre>(f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);</pre>
<pre>(g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);</pre>
(h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j) [_] Group, in accordance with Rule $13d-1(b)(1)(ii)(J)$.
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
Deerfield Capital, L.P 690,115 shares Deerfield Special Situations Fund, L.P 690,115 shares Deerfield Management Company, L.P 1,316,032 shares Deerfield Special Situations Fund International Limited - 1,316,032 shares James E. Flynn - 2,006,147 shares
(b) Percent of class:
Deerfield Capital, L.P 2.23% Deerfield Special Situations Fund, L.P 2.23% Deerfield Management Company, L.P 4.25% Deerfield Special Situations International Limited - 4.25% James E. Flynn - 6.48%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: All Reporting Persons 0
(ii) Shared power to vote or to direct the vote Deerfield Capital, L.P 690,115 Deerfield Special Situations Fund, L.P 690,115 Deerfield Management Company L.P 1,316,032 Deerfield Special Situations Fund International Limited - 1,316,03 James E. Flynn - 2,006,147

(iii) Sole power to dispose or to direct the disposition of

All Reporting Persons - 0

(ii) Shared power to vote or to direct the vote

Deerfield Capital, L.P. - 690,115 Deerfield Special Situations Fund, L.P. - 690,115 Deerfield Management Company, L.P. - 1,316,032 Deerfield Special Situations Fund International Limited - 1,316,032 James E. Flynn -2,006,147

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [_].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B	

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

ı	V,	//	4																																																														
				 -	-	-	-	-	-	-	-	-	-	-	-	-	 	 	 -	-	-	-	-	-	-	 -	-	-	-	-	 -	-	-	-	 -	-	-	-	-	 	 -	-	-	-	-	-	-	 	 	-	-	-	-	-	-	 	-	-	-	-	-	-	-	-	

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

SIGNATURE

	Αf	ter	reaso	onable	inquir	y ar	nd to	the	best	of	my	know	ıled	lge	and	belief,	Ι
certi	fу	that	the	infor	mation	set	forth	ı in	this	sta	atem	ent	is	tru	ie, d	complete	and
correc	ct.																

DEERFIELD CAPITAL, L.P.

By: J.E. Flynn Capital LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Capital, L.P.

By: J.E. Flynn Capital LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LIMITED

By: Deerfield Management Company

By: Flynn Management LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

JAMES E. FLYNN

/s/ Darren Levine

- -----

Darren Levine, Attorney-In-Fact

Date: February 12, 2009

Exhibit List

- Exhibit A. Joint Filing Agreement.
- Exhibit B. Item 8 Statement.
- Exhibit C.(1) Power of Attorney.

(1) Previously field as Exhibit 24 to a Form 4 with regard to PAR Pharmaceutical Companies, Inc. field with the Commission of February 1, 2007 Deerfield Capital L.P.; Deerfield Partners, L.P.; Deerfield Management Company, L.P.; Deerfield International Limited; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International Limited; and James E Flynn.

Exhibit A

Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of AP Pharma Inc. shall be filed on behalf of the undersigned.

	ating to the Common Stock of AP Pharma Inc. shall be ersigned.
DEE	RFIELD CAPITAL, L.P.
Ву:	J.E. Flynn Capital LLC, General Partner
Ву:	/s/ Darren Levine
	Darren Levine, Authorized Signatory
DEE	RFIELD SPECIAL SITUATIONS FUND, L.P.
Ву:	Deerfield Capital, L.P.
Ву:	J.E. Flynn Capital LLC, General Partner
Ву:	/s/ Darren Levine
	Darren Levine, Authorized Signatory
DEE	RFIELD MANAGEMENT COMPANY, L.P.
Ву:	Flynn Management LLC General Partner
Ву:	/s/ Darren Levine
	Darren Levine, Authorized Signatory
DEE	RFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LIMITED
Ву:	Deerfield Management Company
Ву:	Flynn Management LLC, General Partner
Ву:	/s/ Darren Levine
	Darren Levine, Authorized Signatory
JAMI	ES E. FLYNN
101	Parran Lavina

Darren Levine, Attorney-In-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a "group" with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.